Milademetan (tosylate hydrate)
Product Sizes
50 mg
£ POA
HY-101266B-50MG
10 mg
£ POA
HY-101266B-10MG
1 mg
£ POA
HY-101266B-1MG
25 mg
£ POA
HY-101266B-25MG
5 mg
£ POA
HY-101266B-5MG
100 mg
£ POA
HY-101266B-100MG
10mM/1mL
£ POA
HY-101266B-10MM
About this Product
- SKU:
- HY-101266B
- Additional Names:
- DS-3032b; DS-3032 (tosylate hydrate)
- Application:
- Antibody Microarray
- CAS Number:
- 2095625-97-9
- Extra Details:
- Milademetan (DS-3032) tosylate hydrate is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) tosylate hydrate induces G1 cell cycle arrest; senescence and apoptosis[1][2].
- Molecular Weight:
- 808.74
- Purity:
- 98.89
- References:
- [1]ARYL SULFONOHYDRAZIDES. WO 2017069289 A1.|[2]M.M. Gounder, et al. Milademetan, an oral MDM2 inhibitor, in well-differentiated/dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas. European Journal of Cancer 138S2 (2020) S1–S62.|[3]Li, Yangbing, et al. Development of novel PROTAC Small-Molecule Degraders of MDM2 Protein and Peptidomimetic Inhibitors Targeting WDR5-MLL1 Protein-Protein Interaction.|[4]Viktor Arnhold, et al. Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma. ncotarget. 2018 Jan 5; 9(2): 2304–2319.
- Research Area:
- Cancer
- Shipping Conditions:
- Ambient
- Storage Conditions:
- 4[o]C (Powder; sealed storage; away from moisture and light)
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Small Molecules
- Pathway:
- Apoptosis;Metabolic Enzyme/Protease
